SUMO2 Rabbit Polyclonal Antibody
To Order Contact Us Below:
SUMO2 Polyclonal Antibody |
ABP60553-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of SUMO2 from Human, Mouse, Rat. This SUMO2 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human SUMO2 protein at amino acid sequence of 10-90 |
SUMO2 Rabbit pAb |
A1523-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SUMO2 Rabbit pAb |
A1523-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SUMO2 Rabbit pAb |
A1523-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SUMO2 Rabbit pAb |
A1523-50ul |
Abclonal |
50 ul |
EUR 267.6 |
SUMO2 Rabbit pAb |
A2486-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SUMO2 Rabbit pAb |
A2486-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SUMO2 Rabbit pAb |
A2486-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SUMO2 Rabbit pAb |
A2486-50ul |
Abclonal |
50 ul |
EUR 267.6 |
SUMO2 Rabbit pAb |
A2571-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SUMO2 Rabbit pAb |
A2571-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SUMO2 Rabbit pAb |
A2571-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SUMO2 Rabbit pAb |
A2571-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Polyclonal SUMO2/3 Antibody |
APR06632G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 . This antibody is tested and proven to work in the following applications: |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
DLR-SUMO2-Hu-48T |
DL Develop |
48T |
EUR 620.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) in samples from tissue homogenates, cell lysates or other biological fluids. |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
DLR-SUMO2-Hu-96T |
DL Develop |
96T |
EUR 807.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) in samples from tissue homogenates, cell lysates or other biological fluids. |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
RD-SUMO2-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 625.2 |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
RD-SUMO2-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 867.6 |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
RDR-SUMO2-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 652.8 |
Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
RDR-SUMO2-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 907.2 |
SUMO2/3 (SUMO2/3) Antibody |
20-abx008699 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
SUMO2/3 (SUMO2/3) Antibody |
abx026675-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx026675-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx026676-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx026676-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx026683-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx026683-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx238390-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
SUMO2/3 (SUMO2/3) Antibody |
abx238391-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
SUMO2 Antibody |
CSB-PA099258-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
SUMO2 Antibody |
1-CSB-PA05009A0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
SUMO2 Antibody |
1-CSB-PA022949GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
SUMO2 antibody |
70R-20650 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal SUMO2 antibody |
SUMO2 Antibody |
32722-100ul |
SAB |
100ul |
EUR 302.4 |
SUMO2 antibody |
38405-100ul |
SAB |
100ul |
EUR 302.4 |
SUMO2 antibody |
10R-1181 |
Fitzgerald |
100 ul |
EUR 379.2 |
Description: Mouse monoclonal SUMO2 antibody |
SUMO2 Antibody |
CSB-PA099258- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
SUMO2 Antibody |
V7051-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
SUMO2 Antibody |
V7051-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
SUMO2 Antibody |
V7051IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
SUMO2 Antibody |
V7051SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
SUMO2 Antibody |
V2860-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2860-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2860IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2860SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2861-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2861-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2861IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
SUMO2 Antibody |
V2861SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
Anti-Sumo2/3 Rabbit Monoclonal Antibody |
M01282-2 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal Sumo2/3 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat. |
Polyclonal SUMO2 Antibody (aa44-93) |
APR03220G |
Leading Biology |
0.05ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2 (aa44-93). This antibody is tested and proven to work in the following applications: |
Polyclonal SUMO2 Antibody (C-term) |
APR03744G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2 (C-term). This antibody is tested and proven to work in the following applications: |
SUMO2 |
E541-030 |
EnoGene |
100ug |
EUR 411.6 |
Polyclonal SUMO2/3 Antibody (N-term) |
APR03665G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 (N-term). This antibody is tested and proven to work in the following applications: |
Polyclonal SUMO2/3 Antibody (C-term) |
APR03666G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 (C-term). This antibody is tested and proven to work in the following applications: |
SUMO2 Conjugated Antibody |
C32722 |
SAB |
100ul |
EUR 476.4 |
SUMO2/3 antibody |
70R-50404 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal SUMO2/3 antibody |
SUMO2/3 antibody |
70R-30820 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal SUMO2/3 antibody |
SUMO2/3 antibody |
70R-30839 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal SUMO2/3 antibody |
Human SUMO2 Antibody |
32621-05111 |
AssayPro |
150 ug |
EUR 313.2 |
SUMO2/3 Antibody |
5755-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SUMO2/3 Antibody: Small ubiquitin-like modifiers (SUMOs) are a family of small, related proteins (Sumo-1/2/3/4) that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation, which is a major regulator of protein function in cellular processes such as nuclear transport, transcriptional regulation, apoptosis and protein stability. All SUMO proteins localize to the nucleus and are covalently conjugated, affecting protein structure, function and interactions. SUMO2 and 3 are 96% identical and are more mobile within nucleus relative to SUMO1. Specific functional differences between SUMO1 and SUMO2 and 3 remain to be identified. |
SUMO2/3 Antibody |
5755-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SUMO2/3 Antibody: Small ubiquitin-like modifiers (SUMOs) are a family of small, related proteins (Sumo-1/2/3/4) that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation, which is a major regulator of protein function in cellular processes such as nuclear transport, transcriptional regulation, apoptosis and protein stability. All SUMO proteins localize to the nucleus and are covalently conjugated, affecting protein structure, function and interactions. SUMO2 and 3 are 96% identical and are more mobile within nucleus relative to SUMO1. Specific functional differences between SUMO1 and SUMO2 and 3 remain to be identified. |
SUMO2/3 Antibody |
25117-100ul |
SAB |
100ul |
EUR 468 |
Xenopus SUMO2 Antibody |
abx027062-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Xenopus SUMO2 Antibody |
abx027062-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Anti-SUMO2 antibody |
STJ25749 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
Anti-SUMO2 antibody |
STJ28142 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
Anti-SUMO2 antibody |
STJ190176 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Unconjugated Rabbit polyclonal to SUMO2 |
Anti-SUMO2 antibody |
STJ116151 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
SUMO2/3 Antibody |
RQ6517 |
NSJ Bioreagents |
100ug |
EUR 419 |
Description: Small ubiquitin-related modifier 2/3 is a protein that in humans is encoded by the SUMO2/3 gene. This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
SUMO2/3 Antibody |
V2257-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
SUMO2/3 Antibody |
V2257-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
SUMO2/3 Antibody |
V2257IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
SUMO2/3 Antibody |
V2257SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
SUMO2/3 Antibody |
V7091-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
SUMO2/3 Antibody |
V7091-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
SUMO2/3 Antibody |
V7091IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
SUMO2/3 Antibody |
V7091SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
SUMO2 Rabbit Polyclonal Antibody